IKT

1.3201.54%
MT

Mark T. Iwicki

CEO & Director

Mr. Mark T. Iwicki is Director of Nocion Therapeutics, Inc. from April 2026. He has been an Director of Nimbus Therapeutics, Inc. He is Chief Executive Officer and Director of Inhibikase Therapeutics, Inc. from February 14, 2025. Mr. Iwicki serves as Advisor of Atlas Venture Advisors, Inc. (formerly known as Atlas Venture L.P.). since 2025. He has been Director at Q32 Bio Inc since March 2023 and its an Independent Chairman. Mr. Iwicki previously served as the Chairman of Legacy Q32's board of directors since 2020. Mr. Iwicki previously served as the Chairman of Legacy Q32's board of directors since 2020. He had been Chairman of Aerovate Therapeutics, Inc. since February 2021 until March 2024 and served as its Independent Director since February 2021. Mr. Iwicki served as an Independent Chairman of Third Harmonic Bio, Inc. May 2020 until December 2025. He had been the Chairman of the Board of Directors at KALA BIO, Inc. (formerly known as Kala Pharmaceuticals, Inc.) since April 2015 and served as its Director since April 2015 and served as its Chief Executive Officer since September 2015 until February 2025 and had been its President since August 2017 until December 16, 2021 and had been its Director since March 2015 until January 2026. Mr. Iwicki served as Independent Non Executive Director at Merus N.V. since June 1, 2015 until December 11, 2025. He served as the Chairman of the Board at Akero Therapeutics, Inc. since April 2019 until December 9, 2025. Mr. Iwicki served as the Executive Chairman of KALA BIO, Inc. (formerly known as Kala Pharmaceuticals, Inc.) since joining it in April 2015 until September 2015. He has experience as a pharmaceutical industry leader managing all stages of drug development in multiple therapeutic areas. Mr. Iwicki was the Chief Executive Officer and President of Civitas Therapeutics, Inc. /Civitas Pharmaceuticals from January 29, 2014 to November 2014. He has executive management and operational experience in the life science industry. He has extensive experience managing high-performance teams and is instrumental in the success of several drugs, including Prilosec, Diovan, Zelnorm, Lunesta and Latuda. From 2007 to June 2012, Mr. Iwicki served in several roles at Sunovion Pharmaceuticals, Inc. (formerly, Sepracor Inc.). Prior to Civitas, he served as the President and Chief Executive Officer at Tarveda Therapeutics, Inc. (formerly, Blend Therapeutics, Inc.) from December 18, 2012 to January 2014. He served as the President and Chief Executive Officer of Sunovion Pharmaceuticals Inc. from February 19, 2010 to April 11, 2012. He served as an Executive Officer of Sumitomo Dainippon Pharma Co. Ltd. until April 11, 2012. He served as the Chief Operating Officer of Sunovion Pharmaceuticals Inc. since February 19, 2010 until April 11, 2012 and served as its Executive Vice President and Chief Commercial Officer from October 2007 to February 19, 2010. Mr. Iwicki was at Sepracor/Sunovion from October 2007 to June 2012. Prior to joining Sepracor in 2007, he served as the Senior Vice President and Head of the Cardiovascular Business Unit at Novartis Pharmaceuticals and served as management positions at Astra Merck Inc. and Merck & Co. Inc. Prior to joining Sepracor Inc. Mr. Iwicki served at Novartis Pharmaceuticals Corporation from March 1998 to October 2007, where he was Vice President and Business Unit Head. He served as the Chairman of the Board at Merus B.V. since June 5, 2017 until July 2018. He served as Chairman of Pulmatrix, Inc. since December 8, 2015 until April 21, 2020. He served as Director at Pulmatrix, Inc. since December 8, 2015 until July 23, 2021. He has been a Director of LiRIS Biomedical, Inc. since October 2015. He has been a Director of Oxeia Biopharmaceuticals, Inc. since January 2016 and is its Advisory Board Member since 2021 and TARIS BioMedical, Inc. since October 2015. He was a Director of Aimmune Therapeutics, Inc. (formerly, Allergen Research Corporation) since May 18, 2015 until October 13, 2020. He has been a Director of Sepracor, Inc. since February 19, 2010. He was a Director at Civitas Therapeutics, Inc. since January 29, 2014 until September 2014. He serves as a Director of Pharmaceutical Research and Manufacturers of America. He had been an Independent Director of Akero Therapeutics, Inc. since November 2018 until December 9, 2025. He served as a Director of Tarveda Therapeutics, Inc. since December 18, 2012 until January 2014. He served as a Director of Sunovion Pharmaceuticals Inc. from February 19, 2010 to April 11, 2012. He served as the Chairman of Supervisory Board and Member of Supervisory Board at Merus B.V. from June 1, 2015 to June 5, 2017. In addition, Mr. Iwicki has served on the Board of the Wellesley Youth Hockey Association. Mr. Iwicki earned his B.S. in Business Administration and Management from Ball State University and an MBA from Loyola University Maryland.

Positions